Biotechnology

Sanofi and Lonza initiated a joint venture in March of 2017 to create a $285 million biologics manufacturing center in Visp, Switzerland. The strategic partnership leverages Lonza’s expertise in designing, constructing, and managing large-scale mammalian cell culture facilities with Sanofi’s strength in the discovery and launch of biologics-based treatments. Construction is expected to begin in 2017 on the initial phase of the project, with full operations commencing by 2020.

The International Society for Pharmaceutical Engineering (ISPE) announced the annual winners for the Facility of the Year Award (FOYA) program in February of 2017. The category winners were:

The State University of New York (SUNY) Upstate Medical University opened the final phase of its Biotech Accelerator in September of 2016. Located in Syracuse, N.Y., the 60,000-sf facility was designed by The S/L/A/M Collaborative and constructed by Murnane Building Contractors. Providing wet labs, dry labs, and core research space with shared equipment, the project houses the Medical Innovation and Novel Discovery (MIND) Center and the Molecular Pathology Next Generation Sequencing Lab.

Solano Community College is constructing a $34.5 million science and biotechnology training building. Located adjacent to Genentech’s campus in Vacaville, Calif., the 32,200-sf facility will feature simulated production suites for immersive education to support a four-year degree program in biotech manufacturing. The project was designed by SmithGroupJJR and is being built by Rudolph & Sletten.

The College of William & Mary opened the third phase of the Integrated Science Center (ISC3) in September of 2016 in Williamsburg, Va. Accommodating programs in applied science, biology, chemistry, psychology, neuroscience, and computer modeling, the $74 million interdisciplinary facility features 13 chemistry research labs, four teaching labs, instrumentation suites, a computational lab, a biological sciences makerspace, a spectroscopy lab, and a complete machine shop.

GE Healthcare is planning to create a $167 million biopharmaceutical manufacturing campus in Ringaskiddy, Ireland. Featuring GE's prefabricated KUBio™ facilities, GE BioPark Cork will include four KUBio factories owned by independent biopharma companies. GE will manage the campus as well as providing centralized shared utilities and site services. Construction is expected to begin in mid-2017.

The University of Saskatchewan will begin construction in fall of 2016 on the CAD$63 million Collaborative Science Research Building in Saskatoon. The facility will accommodate research on water security and plant science, enabling the development of advanced biofuels, water purification systems, drought-resistant crops, and sustainable pest-control mechanisms. Completion is expected in spring of 2018.

New York Medical College (NYMC), a large private health sciences university in the Hudson Valley, has gut-renovated a portion of the first floor of a former 1970s cancer research center to create a new clinical skills training center, and new biotechnology incubator space near the core campus.

The 23,200-gsf clinical skills training center is a state-of-the-art facility that provides a controlled environment for teaching, observation, and assessment of healthcare-related skills required for the training of medical and other health professions students. 

The Pennsylvania State University is planning a $44.5 million renovation and expansion of the Agricultural Engineering Building in University Park. Providing multidisciplinary laboratories and classrooms, the project will add 35,000 sf to the existing 64,533-sf (44,581-asf) structure. The building houses the Department of Agricultural and Biological Engineering, a department jointly administered by the College of Agricultural Sciences and the College of Engineering.

The University of New South Wales is building the AUD$125 million Biological Sciences Building in Sydney, Australia. Located on the Kensington campus, the 234,000-sf facility will provide teaching and research laboratories for the School of Biological, Earth and Environmental Sciences and the School of Biotechnology and Biomolecular Sciences. Designed by Woods Bagot to optimize flexibility and adaptability, the project will utilize mobile lab benching systems in collaborative research areas located adjacent to support zones with dedicated write-up spaces.

AstraZeneca is building the £750 million Global R&D Centre and Corporate Headquarters on the Cambridge Biomedical Campus in the United Kingdom. Providing advanced facilities for pharmaceutical discovery and development, the 580,000-sf project will include space for biologics research, high throughput screening, medicinal chemistry, pre-clinical research, and clinical studies. Designed to optimize interaction and connectivity, the collaborative 11-acre campus will accommodate approximately 2,000 employees and will include an on-site energy center.

Pfizer broke ground in late June of 2016 on the $350 million Global Biotechnology Center in China. Located in the Hangzhou Economic Development Area (HEDA), the facility will manufacture pharmaceutical biosimilars, which are drugs designed with similar active properties to existing licensed therapies. The project will feature a modular production facility created by GE Healthcare that utilizes flexible, single-use biomanufacturing technologies. The duration of construction will be 18 months with completion expected in early 2018.

JHL Biotech opened a biopharmaceutical manufacturing facility in May of 2016 in Wuhan, China. Featuring single-use bioprocessing technologies, the cGMP facility utilizes GE Healthcare's prefabricated KUBio system to produce biosimilars and monoclonal antibodies for late–stage clinical trials and commercial supply. The project was completed in just 18 months.

Fujifilm Diosynth Biotechnologies opened a 62,000-sf biopharmaceutical manufacturing facility in May of 2016 in Morrisville, N.C. Accommodating collaborative research and development, the three-story BioProcess Innovation Center supports the creation and production of advanced proteins, vaccines, and monoclonal antibodies. The project team included Alexandria Real Estate Equities and KBR Building Group. Ground was broken on the project in January of 2015.

Valent BioSciences is planning to construct the Biorational Research Center at Innovation Park in Libertyville, Ill. Enabling the consolidation of the company's chemistry, biology, microbiology, fermentation, and formulations labs in a single location, the $22 million project includes the buildout of 65,000 sf to create labs and offices as well as the construction of a 10,000-sf research greenhouse. Completion is expected in mid-2017. Valent BioSciences is a subsidiary of Sumitomo Chemical Company.